Trials / Completed
CompletedNCT00285428
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hA20-humanized anti-CD20 antibody | once weekly iv dosing for 4 weeks |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-02-02
- Last updated
- 2021-08-17
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00285428. Inclusion in this directory is not an endorsement.